The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | IFUTURE: building upon the results from IPASS
Tony Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong, discusses how the results from the IPASS (NCT00322452) trial may bridge the gap between our current knowledge of the role of mutant EGFRin lung cancer, and what presently remains unknown in regards to treatment optimization. Prof. Mok discusses the promising treatment avenues, including antibody drug conjugates (ADC), cancer vaccines, and cellular therapy. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
